Impact of the COVID-19 pandemic on patients receiving intravitreal injections
We analyzed the economic benefits versus safety risks of sharing anti-vascular endothelial growth factor (VEGF) vials during the coronavirus disease (COVID-19) pandemic. This single-center retrospective study analyzed the data of patients with neovascular age-related macular degeneration (nAMD), pro...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
University of Belgrade, University of Novi Sad
2022-01-01
|
| Series: | Archives of Biological Sciences |
| Subjects: | |
| Online Access: | http://www.doiserbia.nb.rs/img/doi/0354-4664/2022/0354-46642200003Z.pdf |
| _version_ | 1818011144497922048 |
|---|---|
| author | Zhang Ningzhi He Xuejun Xing Yiqiao Yang Ning |
| author_facet | Zhang Ningzhi He Xuejun Xing Yiqiao Yang Ning |
| author_sort | Zhang Ningzhi |
| collection | DOAJ |
| description | We analyzed the economic benefits versus safety risks of sharing anti-vascular endothelial growth factor (VEGF) vials during the coronavirus disease (COVID-19) pandemic. This single-center retrospective study analyzed the data of patients with neovascular age-related macular degeneration (nAMD), proliferative diabetic retinopathy (PDR) and retinal vein occlusion (RVO) who received anti-VEGF between January 2016 and July 2021 at Renmin Hospital, Wuhan University, China. Costs were compared of the two protocols of intravitreal injections (IVIs) of ranibizumab, aflibercept and conbercept after (i) splitting the vial content for use in two patients and after (ii) disposal of the remaining vial content after use in a single patient, with the COVID-19 outbreak considered as the demarcation point. The incidence rates of post-injection endophthalmitis (PIE) pre- and post-outbreak were analyzed. The mean cost of a single IVI increased by 33.3%, from 3917.67±71.69 to 5222.67±84.98 Chinese Yuan during the pandemic. The incidences of IVI-related culture-positive PIE were 0.0134% (3 in 22448) and 0.0223% (1 in 4479), respectively, before and after the pandemic (P=0.6532). We conclude that vial sharing of IVIs in a large clinical institution is not associated with increased PIE risk and can significantly reduce the cost of therapy. |
| first_indexed | 2024-04-14T06:03:57Z |
| format | Article |
| id | doaj.art-b3186a014f4242f598a8569fd1965f69 |
| institution | Directory Open Access Journal |
| issn | 0354-4664 1821-4339 |
| language | English |
| last_indexed | 2024-04-14T06:03:57Z |
| publishDate | 2022-01-01 |
| publisher | University of Belgrade, University of Novi Sad |
| record_format | Article |
| series | Archives of Biological Sciences |
| spelling | doaj.art-b3186a014f4242f598a8569fd1965f692022-12-22T02:08:39ZengUniversity of Belgrade, University of Novi SadArchives of Biological Sciences0354-46641821-43392022-01-01741495510.2298/ABS220116003Z0354-46642200003ZImpact of the COVID-19 pandemic on patients receiving intravitreal injectionsZhang Ningzhi0He Xuejun1Xing Yiqiao2Yang Ning3Department of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan, ChinaDepartment of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan, ChinaDepartment of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan, ChinaDepartment of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan, ChinaWe analyzed the economic benefits versus safety risks of sharing anti-vascular endothelial growth factor (VEGF) vials during the coronavirus disease (COVID-19) pandemic. This single-center retrospective study analyzed the data of patients with neovascular age-related macular degeneration (nAMD), proliferative diabetic retinopathy (PDR) and retinal vein occlusion (RVO) who received anti-VEGF between January 2016 and July 2021 at Renmin Hospital, Wuhan University, China. Costs were compared of the two protocols of intravitreal injections (IVIs) of ranibizumab, aflibercept and conbercept after (i) splitting the vial content for use in two patients and after (ii) disposal of the remaining vial content after use in a single patient, with the COVID-19 outbreak considered as the demarcation point. The incidence rates of post-injection endophthalmitis (PIE) pre- and post-outbreak were analyzed. The mean cost of a single IVI increased by 33.3%, from 3917.67±71.69 to 5222.67±84.98 Chinese Yuan during the pandemic. The incidences of IVI-related culture-positive PIE were 0.0134% (3 in 22448) and 0.0223% (1 in 4479), respectively, before and after the pandemic (P=0.6532). We conclude that vial sharing of IVIs in a large clinical institution is not associated with increased PIE risk and can significantly reduce the cost of therapy.http://www.doiserbia.nb.rs/img/doi/0354-4664/2022/0354-46642200003Z.pdfanti-vascular endothelial growth factor (vegf)covid-19intravitreal injectionpost-injection endophthalmitisvial splitting |
| spellingShingle | Zhang Ningzhi He Xuejun Xing Yiqiao Yang Ning Impact of the COVID-19 pandemic on patients receiving intravitreal injections Archives of Biological Sciences anti-vascular endothelial growth factor (vegf) covid-19 intravitreal injection post-injection endophthalmitis vial splitting |
| title | Impact of the COVID-19 pandemic on patients receiving intravitreal injections |
| title_full | Impact of the COVID-19 pandemic on patients receiving intravitreal injections |
| title_fullStr | Impact of the COVID-19 pandemic on patients receiving intravitreal injections |
| title_full_unstemmed | Impact of the COVID-19 pandemic on patients receiving intravitreal injections |
| title_short | Impact of the COVID-19 pandemic on patients receiving intravitreal injections |
| title_sort | impact of the covid 19 pandemic on patients receiving intravitreal injections |
| topic | anti-vascular endothelial growth factor (vegf) covid-19 intravitreal injection post-injection endophthalmitis vial splitting |
| url | http://www.doiserbia.nb.rs/img/doi/0354-4664/2022/0354-46642200003Z.pdf |
| work_keys_str_mv | AT zhangningzhi impactofthecovid19pandemiconpatientsreceivingintravitrealinjections AT hexuejun impactofthecovid19pandemiconpatientsreceivingintravitrealinjections AT xingyiqiao impactofthecovid19pandemiconpatientsreceivingintravitrealinjections AT yangning impactofthecovid19pandemiconpatientsreceivingintravitrealinjections |